Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6586 to 6600 of 8899 results

  1. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued Reference number: GID-TAG423

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  3. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  4. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

    Technology appraisal guidance
    Discontinued

  5. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  6. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued Reference number: GID-TAG431

    Technology appraisal guidance
    Discontinued

  7. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  8. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  9. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  10. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  11. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  12. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    In development Reference number: GID-TA11486 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  15. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued